XML 42 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Schedule of Contractual Clinical Trials

The following is a summary of the Company’s ongoing contractual clinical trials described below as of March 14, 2025:

 

Description of Clinical Trial  Institution  Start Date  Projected End Date 

Number of Patients

in Trial

   Study Objective  Clinical Update 

Expected

Date of Preliminary Efficacy

Signal

  NCT No. 

Remaining

Financial

Contractual

Commitment

 
                              
LB-100 combined with atezolizumab in microsatellite stable metastatic colorectal cancer (Phase 1b)  Netherlands Cancer Institute (NKI)  August 2024  December 2026   37   Determine RP2D with atezolizumab  First patient entered August 2024, in total two patients entered  June 2026  NCT06012734   -(1)
                                
LB-100 combined with doxorubicin in advanced soft tissue sarcoma (Phase 1b)  GEIS  June 2023  Recruitment completed September 2024   9 to 18   Determine MTD and RP2D  Fourteen patients entered  December 2025  NCT05809830  $264,000 
                                
Doxorubicin with or without LB-100 in advanced soft tissue sarcoma (Randomized Phase 2)  GEIS  TBD  TBD   150   Determine efficacy: PFS  Clinical trial not yet begun (subject to completion of Phase 1b GEIS clinical trial)  TBD  NCT05809830  $-(1)
                                
LB-100 combined with dostarlimab in ovarian clear cell carcinoma (Phase 1b/2)  MD Anderson  January 2024  December 2027   21   Determine the OS of patients with recurrent ovarian clear cell carcinoma  Nine patients entered  December 2026  NCT06065462   -(1)
                                
Total                            $264,000 

 

(1) The Company has no financial contractual commitment associated with this clinical trial at March 14, 2025.